慢性淋巴细胞白血病膜性肾病对伊鲁替尼反应:1例报告

IF 0.7 Q4 HEMATOLOGY Leukemia Research Reports Pub Date : 2023-01-01 DOI:10.1016/j.lrr.2023.100377

Anna-Eve Turcotte , William F. Glass , Jamie S. Lin , Jan A. Burger

{"title":"慢性淋巴细胞白血病膜性肾病对伊鲁替尼反应:1例报告","authors":"Anna-Eve Turcotte , William F. Glass , Jamie S. Lin , Jan A. Burger","doi":"10.1016/j.lrr.2023.100377","DOIUrl":null,"url":null,"abstract":"<div><p>Membranous nephropathy (MN) is an uncommon renal presentation in patients with chronic lymphocytic leukemia (CLL), and as such, there is no standard therapy for these patients. A few cases of MN in CLL have been described with varying success in MN treatment involving alkylating agents and fludarabine. Here we report the first case of MN in a patient with CLL treated with ibrutinib with complete renal response. This presentation underlines the importance of recognizing rare glomerular diseases that may occur with CLL and offers a new therapeutic avenue to the treatment of CLL-associated MN.</p></div>","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":null,"pages":null},"PeriodicalIF":0.7000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/e9/df/main.PMC10338352.pdf","citationCount":"0","resultStr":"{\"title\":\"Membranous nephropathy in chronic lymphocytic leukemia responsive to ibrutinib: A case report\",\"authors\":\"Anna-Eve Turcotte , William F. Glass , Jamie S. Lin , Jan A. Burger\",\"doi\":\"10.1016/j.lrr.2023.100377\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Membranous nephropathy (MN) is an uncommon renal presentation in patients with chronic lymphocytic leukemia (CLL), and as such, there is no standard therapy for these patients. A few cases of MN in CLL have been described with varying success in MN treatment involving alkylating agents and fludarabine. Here we report the first case of MN in a patient with CLL treated with ibrutinib with complete renal response. This presentation underlines the importance of recognizing rare glomerular diseases that may occur with CLL and offers a new therapeutic avenue to the treatment of CLL-associated MN.</p></div>\",\"PeriodicalId\":38435,\"journal\":{\"name\":\"Leukemia Research Reports\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.7000,\"publicationDate\":\"2023-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/e9/df/main.PMC10338352.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Leukemia Research Reports\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2213048923000171\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Leukemia Research Reports","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2213048923000171","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

膜性肾病(MN)是慢性淋巴细胞白血病(CLL)患者中一种罕见的肾脏表现，因此，对于这些患者没有标准的治疗方法。一些CLL中MN的病例已被描述为在使用烷基化剂和氟达拉滨治疗MN方面取得了不同程度的成功。在这里，我们报告了第一例用依鲁替尼治疗的CLL患者肾反应完全的MN。本报告强调了认识到CLL可能发生的罕见肾小球疾病的重要性，并为CLL相关MN的治疗提供了新的治疗途径。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

摘要图片

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Membranous nephropathy in chronic lymphocytic leukemia responsive to ibrutinib: A case report

Membranous nephropathy (MN) is an uncommon renal presentation in patients with chronic lymphocytic leukemia (CLL), and as such, there is no standard therapy for these patients. A few cases of MN in CLL have been described with varying success in MN treatment involving alkylating agents and fludarabine. Here we report the first case of MN in a patient with CLL treated with ibrutinib with complete renal response. This presentation underlines the importance of recognizing rare glomerular diseases that may occur with CLL and offers a new therapeutic avenue to the treatment of CLL-associated MN.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊